🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT03279276
Active, not recruiting Not applicable

Selecting the Right Hip Prosthesis for Young Patients

NCT03279276 · tracked via the Priya Life Science Denmark tracker
Sponsor
Northern Orthopaedic Division, Denmark
Phase
Not applicable
Started
2018-06-01
Last updated
2022-04-08

Condition(s) studied

Osteoarthritis, Hip

Investigational drug(s) / intervention(s)

Total Hip Arthroplasty

Total Hip Arthroplasty: The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load. By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector.

Study summary

There have been no previously published clinical randomized studies comparing Primoris®, short stem, hip prosthesis with standard uncemented hip arthroplasty in relation to bone density and function development. This is the subject for this study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: Women ≤ 45 years or men ≤ 55 years with hip osteoarthritis, suitable for hip prosthesis. Patients who wish to participate in the project and give written consent after oral and written information. Exclusion Criteria: 1. Patients with previous bone disease, metabolic disease, including diabetes, or the use of drugs that affect bone density. 2. Smoking more than 20 cigarettes daily 3. Patients with fracture in the femur or acetabulum. 4. Patients who do not understand the given patient information 5. Competing disorder requiring treatment with antiinflammatory drugs (NSAIDs, steroid, cytostatics). 6. Estimated residual life \<10 years 7. Rheumatoid arthritis or other arthritis (eg psoriasis arthritis). 8. Previous surgery on the relevant hip joint. 9. Co-Morbidity (ASA Group 3-5). 10. Neurological disorder that compromises motor skills and rehabilitation. 11. Pregnancy. 12. Osteoarthritis secondary to mb. Calvé-Legg-Perthes / Avascular Caput Necrosis, Epiphysiolysis Capitis Femoris and Multiple Epiphysic Dysplasia. 13. Acetabular dysplasia with secondary subluxation (Crowe grade II to IV). 14. Previously detected osteoporosis or osteoporosis detected by current DXA scanning. 15. Ongoing treatment with osteoporosis medicine (bisphosphonates, estrogen receptor modulators and parathyroid hormone, etc.). 16. Aseptic caput necrosis (posttraumatic, idiopathic). 17. Varus or valgus deformity in proximal femur (collum angle \<125 ° or\> 145 °.) 18. Collum femoris assessed too retro- or anteverted.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Northern Orthopaedic Division, Clinic Farsø, Aalborg University Hospital Farsø Northern Jutland

More Northern Orthopaedic Division, Denmark trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03279276 on ClinicalTrials.gov ↗ ← All trials in Denmark